Gabather AB (publ) (STO:GABA)
Sweden · Delayed Price · Currency is SEK 0.0420
-0.0028 (-6.25%)
Jul 17, 2025, 3:51 PM CET
Gabather AB Company Description
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases.
It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease.
The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease.
It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia.
Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
Gabather AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Michael-Robin Witt |
Contact Details
Address: Forskargatan 20J Södertälje, 151 36 Sweden | |
| Phone | 46 7 36 87 28 39 |
| Website | gabather.com |
Stock Details
| Ticker Symbol | GABA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010869552 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael-Robin Witt | Chief Executive Officer and Director |
| Kristofer Svensson | Chief Financial Officer |
| Dr. Christine Ryan | Chief Operating Officer |
| Stefan Rehnmark | C S O |